Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008-Reference-Cited by-同舟云学术

Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008

Published:2010-07-29 Issue:1 Volume:50 Page:117-123
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:Rheumatology

Author:

Hyrich K. L.,Watson K. D.,Lunt M.,Symmons D. P. M.,

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/50/1/117/5062218/keq209.pdf

Reference21 articles.

1. A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

2. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial

3. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial

4. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

5. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimising patient outcomes: temporal trends in remission rates of rheumatoid arthritis patients in the Australian OPAL dataset between 2009 and 2022;Clinical Rheumatology;2024-04-18

2. Association of large joint involvement at the start of biological disease‐modifying antirheumatic drugs and Janus kinase inhibitors with disease activity and drug retention in patients with rheumatoid arthritis: The ANSWER cohort study;International Journal of Rheumatic Diseases;2024-03

3. Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study;RMD Open;2023-08

4. IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study;Rheumatology;2023-06-24

5. Global epidemiology of rheumatoid arthritis;Nature Reviews Rheumatology;2022-09-06